We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has granted orphan-drug status to Lorus Therapeutics' GTI-2040, the
company's lead anticancer drug for the treatment of acute myeloid leukemia (AML).
Corgentech has announced that its NF-kappaB Decoy (NF-kB Decoy) drug candidate
demonstrated a dramatic decrease in inflammation and swelling in preclinical
models of atopic dermatitis, a chronic inflammatory skin disease also known
as eczema.
Cytomedix has completed the planned enrollment of 72 patients in the company's
ongoing clinical trial to test the safety and effectiveness of its AutoloGel
System for the treatment of diabetic foot ulcers.
Marshall Edwards has released preliminary results from a Phase IIa trial in
patients with ovarian cancer that has demonstrated resistance to the standard
first-line chemotherapies of cisplatin and/or paclitaxel.